Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | ARG1 | P05089 | 3/20 | 0.36 |
| ▸ | ARG2 | P78540 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL21796038 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL3094553 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL22157986 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL3100126 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL1675387 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL1675447 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL16038745 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL23834597 | 0.96 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL11660661 | 0.96 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL1696608 | 0.96 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159625-A1 | EXPRESSION OF FC-CONTAINING PROTEINS | GENENTECH INC (US) | 2023-05-25 | — | — | US | claimed |
| US-11591382-B2 | Expression of Fc-containing proteins | GENENTECH, INC. (US) | 2023-02-28 | — | — | US | claimed |
| CN-108138147-B | Expression of Fc-containing proteins | 豪夫迈·罗氏有限公司 | 2022-11-01 | — | — | CN | claimed |
| EP-3699269-A1 | EXPRESSION OF FC-CONTAINING PROTEINS | F. Hoffmann-La Roche AG (CH) | 2020-08-26 | — | — | EP | claimed |
| US-20150132320-A1 | MUTATED ANTI-TNFa ANTIBODIES AND METHODS OF THEIR USE | ABBVIE, INC. | 2015-05-14 | — | — | US | claimed |
| US-20140271626-A1 | MUTATED ANTI-TNFa ANTIBODIES AND METHODS OF THEIR USE | ABBVIE, INC. | 2014-09-18 | — | — | US | claimed |
| US-20230159625-A1 | EXPRESSION OF FC-CONTAINING PROTEINS | GENENTECH INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-11591382-B2 | Expression of Fc-containing proteins | GENENTECH, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| CN-115558028-A | Homodimer type bispecific antibody aiming at B7-H3 and CD3 and preparation method and application thereof | 安源医药科技（上海）有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-108138147-B | Expression of Fc-containing proteins | 豪夫迈·罗氏有限公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-3699269-A1 | EXPRESSION OF FC-CONTAINING PROTEINS | F. Hoffmann-La Roche AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| US-20180282398-A1 | EXPRESSION OF FC-CONTAINING PROTEINS | GENENTECH INC (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3353288-A1 | EXPRESSION OF FC-CONTAINING PROTEINS | H. Hoffnabb-La Roche Ag (CH) | 2018-08-01 | — | — | EP | disclosed |
| WO-2004038003-A2 | HUMAN POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES AND METHODS OF THEIR USE | FIVE PRIME THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004035732-A2 | HUMAN POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES AND METHODS OF THEIR USE | FIVE PRIME THERAPEUTICS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004020591-A2 | METHODS OF USE FOR NOVEL HUMAN POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES | FIVE PRIME THERAPEUTICS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004020595-A2 | NOVEL HUMAN POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES | FIVE PRIME THERAPEUTICS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1034283-A2 | GENETIC ENGINEERING OF LIGNIN BIOSYNTHESIS IN PLANTS | Board of Control of Michigan Technological University (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999024561-A2 | GENETIC ENGINEERING OF LIGNIN BIOSYNTHESIS IN PLANTS | BOARD OF CONTROL OF MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 1999-05-20 | — | — | WO | disclosed |
| US-4921941-A | TRIPEPTIDE ESTERS | SCHERING CORPORATION (US) | 1990-05-01 | — | — | US | disclosed |